Exploratory efficacy of opicapone in fluctuating Parkinson’s disease patients at different stages of symptom progression
Objective: Evaluate the efficacy of opicapone (OPC) in fluctuating Parkinson's disease patients at different stages of symptom progression over a 14-15 week treatment period. Background:…Activities of daily living and motor scores of the UPDRS in fluctuating Parkinson’s disease patients treated with opicapone
Objective: Evaluate the effects of opicapone (OPC) on the activities of daily living and motor scores of the UPDRS in fluctuating Parkinson's disease patients. Background:…Evaluation of impulse control disorders in fluctuating Parkinson’s disease patients under opicapone treatment
Objective: Evaluate the impulse control disorders reported as adverse events in phase III studies with opicapone (OPC) in fluctuating Parkinson's disease patients. Background: Impulse control…Improving drug discovery using brain oscillations as biomarkers of Parkinson’s disease
Objective: The aim of this study was to assess the use of cortical oscillations as translational biomarkers for drug development for the motor symptoms of…Utilization and longitudinal impact of anticholinergic use in Parkinson’s disease. National Parkinson Foundation (NPF) QII registry
Objective: To evaluate baseline predictors and longitudinal impact of anticholinergics use in Parkinson's disease (PD). Background: Anticholinergics have beneficial effect on tremor in PD but…Experience with utilization of rytary in the clinical setting
Objective: To explore the utilization and tolerability of Rytary in the clinical setting. Background: Rytary is a novel extended-release carbidopa-levodopa (CD-LD) formulation that was approved…Improvement of freezing of gait with intestinal levodopa infusion in advanced Parkinson’s disease patients
Objective: To determine whether levodopa-carbidopa intestinal gel (LCIG) infusion is able to improve freezing of gait (FOG) in advanced Parkinson's disease (PD) patients. Background: FOG…Dopamine dysregulation syndrome /DDS/ in LCIG infusion: Successful treatment without interrupting the pump therapy
Objective: Here we report the case of a 49-year-old man with a 19 years history of PD presenting DDS while he was on LCIG therapy.…Safety and efficacy of pardoprunox for patients with Parkinson’s disease: A meta-analysis
Objective: The aim of this meta-analysis is to synthesize evidence from published randomized controlled trials (RCTs) about the safety and efficacy of Pardoprunox for Patients…Objective measurement in clinical care of patients with Parkinson’s disease
Objective: To establish whether using the Parkinson's KinetiGraph™ which provides objective measures in activities of daily living, helps identify unknown poorly controlled patients with Parkinson's…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.